MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Y.
Right arrow Articles by Lee, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Y.
Right arrow Articles by Lee, J.

Vol. 62, Issue 4, 947-956, October 2002

High Affinity Antagonists of the Vanilloid Receptor

Yun Wang,1 Tamas Szabo, Jacqueline D. Welter, Attila Toth, Richard Tran, Jiyoun Lee, Sang Uk Kang, Young-Ger Suh, Peter M. Blumberg, and Jeewoo Lee

National Cancer Institute, Bethesda, Maryland (Y.W., T.S., J.D.W., A.T., R.T., P.M.B.); and College of Pharmacy, Seoul National University, Seoul, Korea (Ji.L., S.U.K., Y.-G.S., Je.L.)

The vanilloid receptor VR1 has attracted great interest as a sensory transducer for capsaicin, protons, and heat, and as a therapeutic target. Here we characterize two novel VR1 antagonists, KJM429 [N-(4-tert-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea] and JYL1421 [N-(4-tert-butylbenzyl)-N'-[3-fluoro-4-(methylsulfonylamino)benzyl]thiourea], with enhanced activity compared with capsazepine on rat VR1 expressed in Chinese hamster ovary (CHO) cells. JYL1421, the more potent of the two novel antagonists, inhibited [3H]resiniferatoxin binding to rVR1 with an affinity of 53.5 ± 6.5 nM and antagonized capsaicin-induced calcium uptake with an EC50 of 9.2 ± 1.6 nM, reflecting 25- and 60-fold greater potencies than capsazepine. Both JYL1421 and KJM429 antagonized RTX as well as capsaicin and their mechanism was competitive. The responses to JYL1421 and KJM429 differed for calcium uptake by rVR1 induced by heat or pH. JYL1421 antagonized the response to both pH 6.0 and 5.5, whereas KJM429 antagonized at pH 6.0 but was an agonist at lower pH (<5.5). For heat, JYL1421 fully antagonized and KJM429 partially antagonized. Capsazepine showed only weak antagonism for both pH and heat. Responses of rVR1 to different activators could thus be differentially affected by different ligands. In cultured dorsal root ganglion neurons, JYL1421 and KJM429 likewise behaved as antagonists for capsaicin, confirming that the antagonism is not limited to heterologous expression systems. Finally, JYL1421 and KJM429 had little or no effect on ATP-induced calcium uptake in CHO cells lacking rVR1, unlike capsazepine. We conclude that JYL1421 is a competitive antagonist of rVR1, blocking response to all three of the agonists (capsaicin, heat, and protons) with enhanced potency relative to capsazepine.

1 Present address: Neuroscience Research Institute, Peking University, 100083, Beijing, People's Republic of China.

Copyright © 2002 by U.S. Government


This article has been cited by other articles:


Home page
 Mol. Interv.Home page
P. M. Blumberg
Lighting a Backfire to Quench the Blaze: A Combined Drug Approach Targeting the Vanilloid Receptor TRPV1
Mol. Interv., December 1, 2007; 7(6): 310 - 312.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. Tang, Y. Chen, Z. Chen, P. M. Blumberg, A. P. Kozikowski, and Z. J. Wang
Antinociceptive Pharmacology of N-(4-Chlorobenzyl)-N'-(4-hydroxy-3-iodo-5-methoxybenzyl) Thiourea, a High-Affinity Competitive Antagonist of the Transient Receptor Potential Vanilloid 1 Receptor
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 791 - 798.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. E. Johansen, C. A. Reilly, and G. S. Yost
TRPV1 Antagonists Elevate Cell Surface Populations of Receptor Protein and Exacerbate TRPV1-Mediated Toxicities in Human Lung Epithelial Cells
Toxicol. Sci., January 1, 2006; 89(1): 278 - 286.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
N. R. Gavva, R. Tamir, L. Klionsky, M. H. Norman, J.-C. Louis, K. D. Wild, and J. J. S. Treanor
Proton Activation Does Not Alter Antagonist Interaction with the Capsaicin-Binding Pocket of TRPV1
Mol. Pharmacol., December 1, 2005; 68(6): 1524 - 1533.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. El Kouhen, C. S. Surowy, B. R. Bianchi, T. R. Neelands, H. A. McDonald, W. Niforatos, A. Gomtsyan, C.-H. Lee, P. Honore, J. P. Sullivan, et al.
A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel and Selective Transient Receptor Potential Type V1 Receptor Antagonist, Blocks Channel Activation by Vanilloids, Heat, and Acid
J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 400 - 409.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
B Schmidt, J Hammer, P Holzer, and H F Hammer
Chemical nociception in the jejunum induced by capsaicin
Gut, August 1, 2004; 53(8): 1109 - 1116.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Toth, P. M. Blumberg, Z. Chen, and A. P. Kozikowski
Design of a High-Affinity Competitive Antagonist of the Vanilloid Receptor Selective for the Calcium Entry-Linked Receptor Population
Mol. Pharmacol., February 1, 2004; 65(2): 282 - 291.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Y. Wang, A. Toth, R. Tran, T. Szabo, J. D. Welter, P. M. Blumberg, J. Lee, S.-U. Kang, J.-O. Lim, and J. Lee
High-Affinity Partial Agonists of the Vanilloid Receptor
Mol. Pharmacol., August 1, 2003; 64(2): 325 - 333.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics